Jennifer Altomonte

Jennifer Altomonte is the CEO and a co-founder of Fusix Biotech, which was founded in March 2022 as a university spin-out from the Technical University of Munich (TUM) in Germany. Jennifer is the inventor of the Fusix technology, which is an immunotherapy platform for solid cancers that is based on a propriety oncolytic virus vector. She is a molecular biologist and virologist with over 20 years of experience in viral engineering and the development of oncolytic viral cancer immunotherapeutics. She was trained at the Pennsylvania State University (USA) and received her doctoral degree from TUM, where she additionally leads an academic research group within the Internal Medicine Department II at the Klinikum rechts der Isar in Munich.